We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
The Collagen Supplements Market was valued at USD 2.3 Bn in 2023. It is expected to reach USD 3.7 Bn by 2033, with a CAGR ...
The last year (and particularly the last few months) of the Biden Administration brought a flurry of activity from the Federal Trade Commission ...
This interactive two-day course has been designed to provide you with a thorough understanding of both technical and interpersonal project management skills.
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...
The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...
Sanofi’s Dupixent has been granted FDA priority review for the treatment of bullous pemphigoid (BP), a chronic skin disease. If approved, Dupix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback